Please use this identifier to cite or link to this item:
Title: Sunitinib-induced adrenal crisis in a patient with pre-existing immunotherapy-related hypopituitarism.
Author: Javaid, Aanadil
Mathai, Jared
Song, David
Brown, Stephen
Issue Date: 2022
Publication Title: Case Reports in Oncology
Volume: 15
Start Page: 1
End Page: 6
Abstract: Sunitinib is a tyrosine kinase inhibitor that is frequently used in the treatment of metastatic renal cell carcinoma (mRCC). As a multikinase inhibitor, numerous off-target side effects of this medication are widely recognized. More recently, endocrine side effects, including hypoadrenalism, are becoming more apparent. We report a case in which a 71-year-old female experienced recurrent adrenal crises when managed with sunitinib for mRCC on a background of immune-related hypopituitarism and hypoadrenalism as a result of previous treatment with immunotherapy. Clinicians should be aware of this potential toxicity when using such medications and consider further investigation in the appropriate clinical setting.
Internal ID Number: 01864
Health Subject: SUNITINIB
Type: Journal Article
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.